Verastem, Inc. (VSTM)
Verastem develops and markets cancer medicines that target the RAS/MAPK pathway, including an approved ovarian cancer treatment. It last closed at $7.41 on Nov 17, down 3.77% on the day. The average 12-month price target from 4 analysts is $18.75 (+153.0% from the last close), with a high of $24.00 and a low of $13.00. Analyst consensus is Strong Buy, based on the latest ratings from 4 firms (4 buy, 0 hold, 0 sell). Over the past 90 days StreetAlpha recorded 1 whale options trade in VSTM, 0% of them bullish and 100% bearish. In the past 30 days there were 3 dark pool prints totaling $1.3M, the largest $513K.
Key Stats
Last 12 monthsNot reported for this period.
From VSTM's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 4 analysts who set a price target on VSTM in the past 90 days. The average target is $18.75, with a high of $24.00 and a low of $13.00, compared with the last close of $7.41.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 6 | RBC Capital | Target lowered | Buy | $19 → $18 |
| Nov 6 | HC Wainwright & Co. | Maintained | Buy | $20 |
| Oct 19 | BTIG | Reiterated | Buy | $24 |
| Oct 15 | Jefferies | Target raised | Buy | $8 → $13 |
| Oct 15 | RBC Capital | Target raised | Buy | $14 → $19 |
Technical Analysis
The stock is 24% below its 20 day and 14% below its 50 day average. It is 15% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 35), near oversold. The nearest support is the swing low (Sep 28) at $7.39, and the nearest resistance the Pivot at $7.55.
| RSI (14) | 35.08 | Weak, oversold below 30 | Neutral |
| MACD | -0.18 | Below its signal line | Bearish |
| Stochastic | 6.5 | Near the bottom of its range | Oversold |
| ADX (14) | 29.4 | Trending down | |
| Williams %R | -98.0 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -164.9 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −24.2% | Change over 10 sessions | Bearish |
| ATR (14) | $0.64 | Typical daily range, 8.7% of price |
| RSI (14) | 50.62 | Middle of its range | Neutral |
| MACD | 0.69 | Above its signal line | Bullish |
| Stochastic | 44.3 | Middle of its range | Neutral |
| ADX (14) | 30.4 | Trending up | |
| Williams %R | -74.7 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | 13.5 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | +1.2% | Change over 10 sessions | Bullish |
| ATR (14) | $1.23 | Typical daily range, 16.7% of price |
What happened before
See how VSTM did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How VSTM has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2012.
Whale Options Flow
90DNo whale options trades in VSTM in the last 90 days.
Dark Pool
30DVSTM Institutional Ownership
Full report →- ▲94 buying vs 73 selling
- ▼Held by funds -8.4 pts
- ▲Funds holding +4
- ●Superinvestors: 2 added, 2 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 162 | 158 | +2.5% |
| In funds' top 10 | 5 | 2 | +150.0% |
| Held by funds | 70.1% | 78.5% | −8.4 pts |
| New / increased | 35 / 59 | 33 / 70 | −8.7% |
| Reduced / sold out | 44 / 29 | 34 / 28 | +17.7% |
| Put/call ratio | 0.00 | 0.00 | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether VSTM is in one of them and how their past VSTM trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered VSTM in an article yet. Here's the latest on the wider market.
About Verastem
Verastem is a biopharmaceutical company based in Needham, Massachusetts, that develops and sells medicines for cancers driven by the RAS/MAPK pathway. Its approved product, AVMAPKI FAKZYNJA CO-PACK, is marketed in the United States to adults with recurrent low grade serous ovarian cancer that has KRAS mutations and who have had prior systemic therapy. Its pipeline includes VS-7375, an oral KRAS G12D inhibitor being studied in pancreatic, lung and colorectal cancers. Its customers are cancer patients and the physicians who treat them.
- Headquarters
- Needham, MA



